Pamela Wapnick Biography and Net Worth

CFO of Metagenomi

Pamela Wapnick has more than 20 years of diversified financial leadership experience spanning strategic and operational finance roles.

Prior to joining Metagenomi, Pamela served as Chief Financial Officer at several biotech and medical technology companies including Diality, Capsida Biotherapeutics, and Graybug Vision, where she built the finance functions and led financial planning and strategy.

As Chief Financial Officer at True North Therapeutics, Pamela completed preparations for an initial public offering before the company’s acquisition by Bioverativ. Prior to that, she served in various executive leadership roles at Amgen, including Corporate Treasurer and Vice President R&D Finance, where she was responsible for a $3 billion global R&D budget focused on advancing research and pipeline programs. Pamela holds an MBA from Columbia University and a BA in Economics from Wellesley College.

What is Pamela Wapnick's net worth?: The estimated net worth of Pamela Wapnick is at least $240.81 thousand as of June 5th, 2026. Ms. Wapnick owns 208,491 shares of Metagenomi stock worth more than $240,807 as of September 25th. This net worth evaluation does not reflect any other assets that Ms. Wapnick may own. Learn More about Pamela Wapnick's net worth.
How do I contact Pamela Wapnick?: The corporate mailing address for Ms. Wapnick and other Metagenomi executives is 5959 Horton Street, 7th Floor, Emeryville, CA, 94608. Metagenomi can also be reached via phone at 510-871-4880 and via email at [email protected]. Learn More on Pamela Wapnick's contact information.
Has Pamela Wapnick been buying or selling shares of Metagenomi?: Pamela Wapnick has not been actively trading shares of Metagenomi in the last ninety days. Most recently, Pamela Wapnick sold 2,884 shares of the business's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $1.30, for a transaction totalling $3,749.20. Following the completion of the sale, the chief financial officer now directly owns 208,491 shares of the company's stock, valued at $271,038.30. Learn More on Pamela Wapnick's trading history.
Who are Metagenomi's active insiders?: Metagenomi's insider roster includes Laurence Reid (Director), Brian Thomas (Founder & Former CEO), and Pamela Wapnick (CFO). Learn More on Metagenomi's active insiders.
Are insiders buying or selling shares of Metagenomi?: During the last year, Metagenomi insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $23,400.00. During the last year, insiders at the sold shares 4 times. They sold a total of 9,871 shares worth more than $15,847.42. The most recent insider tranaction occured on September, 9th when Director Laurence Reid bought 20,000 shares worth more than $23,400.00. Insiders at Metagenomi own 12.5% of the company. Learn More about insider trades at Metagenomi.
Information on this page was last updated on 9/9/2026.

Pamela Wapnick Insider Trading History at Metagenomi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/5/2026	Sell	2,884	$1.30	$3,749.20	208,491
3/5/2026	Sell	1,581	$1.60	$2,529.60	187,375
12/5/2025	Sell	1,576	$1.77	$2,789.52	188,956
9/5/2025	Sell	1,576	$1.81	$2,852.56	70,532
6/6/2025	Sell	1,576	$1.75	$2,758.00	72,108
12/5/2024	Sell	1,559	$1.86	$2,899.74	61,492
9/5/2024	Sell	6,265	$2.88	$18,043.20	63,051

Pamela Wapnick Buying and Selling Activity at Metagenomi

Metagenomi Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Today's Range

Now: $1.16

$1.14

$1.17

50 Day Range

MA: $1.19

$1.10

$1.24

2 Week Range

Now: $1.16

$1.07

$3.95

Volume

28,331 shs

Average Volume

197,424 shs

Market Capitalization

$43.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67